GlassScriptPhysician profile
Katherine Chin
NPI 1285830356
$2,051.19
in general payments reported to CMS, 2019-2025
26 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.11 · 2020: $250 · 2021: $381 · 2022: $369 · 2023: $369 · 2024: $349 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.58 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $289.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $105.56 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $88.85 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.47 | 2020-2021 | |
| Pfizer INC. | $83.55 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $72.41 | 2020-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $70.15 | 2020-2025 | Gardasil 9, Gardasil, Capvaxive |
| Gilead Sciences, INC. | $68.90 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $66.47 | 2022-2025 | Breztri, Airsupra |
| Dexcom, INC. | $55.40 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.79 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $39.52 | 2022-2023 | Shingrix |
| Allergan, INC. | $34.35 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.11 | 2024 | Glassia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.57 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $26.23 | 2020 | |
| Adlon Therapeutics L.P. | $24.60 | 2021 | |
| Biogen, INC. | $24.32 | 2024 | Leqembi |
| Amarin Pharma, INC. | $23.90 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.00 | 2022 | |
| Eisai INC. | $18.94 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $18.05 | 2025 | Neffy |
| Phadia US INC. | $17.01 | 2024 | Immunocap |
| Sanofi Pasteur INC. | $15.35 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.09 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.